{"organizations": [], "uuid": "ee9e799e9787c2f22fb821336a28ddfda8b61034", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KD535_0903bi_G_20150903141717.jpg", "site_section": "http://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/big-pharma-the-moment-of-dread-is-here-1441307449", "country": "US", "title": "Big Pharma: The Moment of Dread Is Here", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Big Pharma: The Moment of Dread Is Here - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-09-03T23:10:00.000+03:00", "replies_count": 0, "uuid": "ee9e799e9787c2f22fb821336a28ddfda8b61034"}, "author": "Charley Grant", "url": "http://www.wsj.com/articles/big-pharma-the-moment-of-dread-is-here-1441307449", "ord_in_thread": 0, "title": "Big Pharma: The Moment of Dread Is Here", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "The initial stakes are low for the imminent launch of the first U.S. biosimilar drug. Pharmaceutical companies that develop branded drugs shouldn’t expect them to stay that way.\nSandoz, the generics arm of European pharmaceutical giant Novartis, announced on Thursday that it will begin selling Zarxio, its biosimilar answer to Amgen’s Neupogen, in the U.S. The launch begins after a U.S. appeals court denied Amgen’s latest request to... ", "external_links": [], "published": "2015-09-03T23:10:00.000+03:00", "crawled": "2015-09-03T22:50:02.804+03:00", "highlightTitle": ""}